The global coronary artery bypass grafts market is projected to be valued at USD 18.7 billion in 2025 and is expected to reach USD 24.8 billion by 2035, registering a CAGR of 2.9%. This market is currently experiencing steady expansion driven by the rising global burden of coronary artery disease and increased adoption of minimally invasive and robotic-assisted techniques.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 18.7 billion |
| Industry Value (2035F) | USD 24.8 billion |
| CAGR (2025 to 2035) | 2.9% |
Over the next few years, growth will be underpinned by accelerated deployment of next‑generation grafts and enhanced OPCAB (off‑pump) procedures improving patient outcomes. Surge in market penetration as hospitals invest in advanced cardiac infrastructure, supported by government‑led cardiovascular disease initiatives and expanded health insurance access.
Industry leaders such as Medtronic Plc., Terumo Corporation, Edwards Lifesciences, Getinge AB, and Genesee Biomedical continue to dominate through focused R&D on minimally invasive platforms, hybrid operating systems with development of advanced graft materials. These companies are expanding their influence by forging strategic collaborations integrating AI‑enabled intraoperative tools, and launching training programs to enhance OPCAB technique adoption.
In 2025, AMT Medical B.V., announced a USD 25 million Series B financing round led by Bender Analytical Holding B.V. (BAH). The funding accelerates the development of AMT’s ELANA® Heart Bypass System, a minimally invasive solution designed to replace traditional open-heart bypass surgery, ultimately leading to robot-assisted keyhole surgery compatible with surgical robots from industry leaders.
“This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes – we’re redefining cardiovascular care.” Said Rutger Tulleken, CEO & Co-Founder of AMT Medical.
North America maintains leadership within the CABG market, driven by high procedural volumes and advanced reimbursement frameworks. Key factors influencing growth includes widespread integration of robotic-assisted and OPCAB procedures, supported by centres of excellence in hybrid cardiac operating rooms.
Innovators such as Medtronic and Genesee Biomedical are actively collaborating with integrated health systems to pilot AI‑guided graft selection and 3D‑printed bio grafts. This region also benefits from strong insurer and Medicare support for novel CABG technologies, accelerating clinical adoption.
Europe is embracing minimally invasive CABG, particularly in Germany, France, and Nordic countries, where hybrid ORs and robot‑assisted systems have seen accelerated diffusion. Regulatory frameworks like the EU MDR are incentivizing adoption of bioengineered and drug‑eluting grafts, especially in tertiary cardiac centres.
Partnerships between device manufacturers and public healthcare systems are rolling out pilot programs for OPCAB and arterial graft technologies. Moreover, Europe’s emphasis on post‑operative outcomes has led to expanded use of AI‑driven tele‑monitoring models, reducing readmission rates and enhancing patient throughput.
Off-pump CABG has been observed to dominate the market in 2025, accounting for approximately 51.8% of the total revenue share. Its growth has been attributed to advancements in beating-heart surgical techniques that eliminate the need for cardiopulmonary bypass, thereby reducing operative risks.
The segment’s expansion has been driven by its association with lower post-operative complications, shortened hospital stays, and improved long-term outcomes, particularly in elderly and comorbid populations. Supportive training programs for surgeons and favorable clinical outcomes reported in comparative studies have reinforced its adoption across high-volume cardiac centers. Furthermore, innovation in stabilizing instruments and imaging-guided grafting tools has made the procedure more accessible.
Single CABG surgery has been found to hold a 34.6% share in the global market by 2025, driven by its role in early-stage coronary artery disease management. The segment’s growth has been influenced by rising health screening programs and increased diagnosis of isolated coronary artery blockages, which are managed more effectively with single graft interventions.
Minimally invasive surgical advancements have enabled the safer execution of single bypass procedures, especially in outpatient or short-stay hospital settings. Demand has also been supported by aging populations experiencing early cardiac symptoms that require less extensive revascularization.
Adoption has further been encouraged by lower procedural risk, quicker recovery, and reduced cost burden compared to multi-vessel procedures. Additionally, single CABG is often recommended for high-risk patients where complex surgeries are contraindicated.
Hospitals have emerged as the leading end-user segment, accounting for 49.0% of the revenue share in 2025. This dominance has been attributed to the availability of advanced cardiovascular surgical infrastructure, including hybrid operating rooms, robotic systems, and post-operative intensive care units.
Most coronary artery bypass procedures continue to be centralized in hospital settings due to the need for comprehensive pre-operative diagnostics and high-acuity recovery care. Increased patient admissions, higher surgical throughput, and integrated insurance reimbursements have further consolidated hospital dominance. Government investments in cardiac care programs and hospital accreditation systems have also enhanced patient trust and procedural uptake, sustaining the segment's leadership position.
Challenges
Increasing Preference for Percutaneous Coronary Interventions (PCI) Creating Barrier in Product Adoption
One of the greatest challenges facing the CABG market is the rise in preference for percutaneous coronary interventions (PCI), including angioplasty and drug-eluting stents (DES). PCI procedures are minimally invasive, involve shorter periods of recovery, and are commonly less expensive, thus becoming the first preference of most patients and cardiologists.
A second major challenge is the prohibitive cost of CABG procedures. The requirement of specialized surgical teams, sophisticated hospital facilities, and post-operative management renders CABG a costly mode of treatment, especially in low- and middle-income countries. Even in industrialized countries, insurance restrictions and differences in reimbursement policies influence patient accessibility.
Secondarily, post-surgical complications involving graft failure, infections, and stroke risk concern patients and doctors alike. Late venous graft durability is an ongoing problem and, therefore, more preference goes towards the arterial grafts requiring more advanced operative skills.
Opportunities
Growing Interest in Robotic-Assisted CABG and Hybrid Revascularization Procedures Creating Opportunities for the Coronary Artery Bypass Graft Industry
Robotic-assisted coronary artery bypass grafting (CABG) and hybrid revascularization surgeries are transforming the management of advanced coronary artery disease (CAD). Robotic-assisted CABG is a minimally invasive surgical method that employs robotic systems to execute extremely accurate graft placements, minimizing trauma, shortening recovery periods, and enhancing surgical results.
Hybrid revascularization, which uses both CABG and PCI in conjunction, has been implemented for its individualized delivery aimed at maximizing the results in terms of the patient, with an appeal specifically in those cases when open-heart surgery may be inapplicable or insufficient due to risks to the patient.
Growing use of robotic-assisted methods and hybrid surgery is boosting demand for sophisticated operating equipment, robot systems, and specialized grafts. Cardiac centers and hospitals are deploying robotic platforms and training initiatives to increase their capabilities in minimally invasive CABG, thereby increasing the market for associated medical devices. Further, with more clinical trials supporting long-term advantages of these procedures, physician confidence and patient preference for these procedures are also on the rise.
This trend is presenting considerable sales prospects for medical technology firms producing robotic surgical systems, anastomotic devices, and bioengineered grafts, putting them in a position to take advantage of the increased move toward novel CABG solutions.
From 2020 to 2024, the coronary artery bypass graft (CABG) market has witneed consistent growth with increasing incidence of coronary artery disease (CAD), a growing aging world population, and lifestyle-related risk factors like obesity, diabetes, and hypertension. Technology evolution, like off-pump CABG procedures and minimally invasive surgical methods, enhanced patient outcomes and shortened recovery times.
But the growing popularity of percutaneous coronary interventions (PCI), including stenting, was challenging conventional CABG procedures. Excessive procedural cost and complications after surgery were the major challenges.
Coming into 2025 to 2035, market developments will be led by innovation in bioengineered grafts, AI-powered surgical planning, and robotic-assisted bypass. Regulatory infrastructures will find ways to embrace improvements in tissue-engineered grafts and minimal-access CABG technologies.
Rising access to healthcare in developing nations and increased government initiatives for treating cardiovascular disease will lead to expanding market opportunities. Sustainability will involve reducing environmental footprints through the use of biodegradable graft material and efficient energy-using operating room technology. Regionalization of production for medical devices will enhance supply chain resilience as well as availability of quality graft materials.
Revolutionary technology is fuelling the growth of the United States CABG market. Cardiovascular diseases (CVD), particularly Coronary artery disease (CAD), continues to be the leading cause of death in many countries. Growing CABG need is also driven by demographic changes related to aging population, obesity, and increasing prevalence rates of diabetes.
Technological evolution including off-pump and minimally invasive coronary artery bypass (MIDCAB) has not only ushered greater care for the patient with lesser postoperative complications and quicker recovery. Dominant firms, such as Medtronic and Edwards Lifesciences, in the medical device industry fuel innovation in graft materials and instruments.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 1.4% |
Germany's industry outlook remains steady, supported by the healthcare system, advanced surgical department and increasingly adopted medical study. Cardiovascular disease is an enormous public health problem, and more patients require surgery. Hybrid revascularization procedures, combining CABG and PCI, are gaining popularity and improving patient's outcomes.
Germany is also leading the way in robotic-assisted and endoscopic CABG procedures, minimizing invasiveness and hospitalization. Government health policies and reimbursement schemes guarantee access to high-quality surgical procedures, further fueling market growth.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 1.8% |
India's CABG market is reporting strong growth due to a rise in cardiovascular diseases and healthcare awareness. India has one of the highest CAD burdens globally with more than 60 million people suffering from heart disease. India has experienced rapid growth in cardiac specialty hospitals and the use of advanced surgical methods such as beating-heart surgery and off-pump CABG.
Affordability of medical care relative to Western nations has also established India as a medical tourism destination for foreign patients who are looking for high-quality yet affordable CABG procedures. Efforts by the government to increase access to healthcare, including Ayushman Bharat, are rendering advanced cardiac interventions more affordable for poor populations.
Market Growth Factors
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 6.7% |
The growth of CABG in China is rapid, owing primarily to the rising cases of cardiovascular disorder in China resulting from increased urbanization, physical inactivity, and smoking. Due to its population of more than 330 million patients with cardiovascular diseases, China has the largest global needs for cardiac interventional therapy.
The government has been putting significant financial resources into the health care infrastructure, and as a direct outcome the count of hospitals which can perform CABG surgery has grown Chinese medical institutions and scientists have also worked together with overseas companies to implement new forms of surgery, such as minimally invasive and robot-assisted CABG. In spite of these developments, inequality in access to healthcare between rural and urban areas and the affordability of surgery continue to be issues.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| China | 5.9% |
The Brazil CABG market is likely to grow steadily during the forthcoming years, owing to the increasing prevalence of cardiovascular diseases, burgeoning healthcare expenditure, and improved surgical infrastructure in the territory. The country has experienced an uninterrupted increase in cases of CAD due to widespread obesity, hypertension, and diabetes.
The growth of the market is driven by increased government initiatives in improving cardiac care through more public hospital facilities and dedicated heart centers, etc. Also, private hospitals are making investments to upgrade the surgery facilities and use for minimally invasive way for Coronary artery bypass grafting. Economic inequalities and restricted access to sophisticated care in rural areas are creating hurdles.
Market Growth Drivers
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 1.1% |
The coronary artery bypass graft (CABG) market is growing on account of rising cases of cardiovascular diseases, growing geriatric population, and expansion of minimally invasive surgical techniques.
Some of the key factors of competitive advantage for the market players are focusing on the new graft materials development, expanding in international markets and conducting studies for improved treatment outcomes. The market is very competitive with established medical device players and new companies launching next-generation CABG solutions.
Medtronic plc (27.7%)
Medtronic is building its presence in emerging economies by enhancing distribution networks and local partnerships with healthcare providers. It is also making investments in advanced bioengineered grafts for better long-term patency and lower risks of restenosis. Medtronic's value-based healthcare model focus enables hospitals to implement its CABG solutions by providing flexibility in pricing and reimbursement models.
Furthermore, Medtronic is combining machine learning algorithms with surgical planning software to optimize accuracy and anticipate patient results. These tactics individually place the firm at the forefront of traditional as well as robot-assisted CABG operations.
Terumo Corp (17.0%)
Terumo is concentrating on enlarging its portfolio of offerings in the form of high-performing surgical grafts and superior cardiopulmonary bypass technology. The firm is also investing in localized Asian and European manufacturing and R&D facilities to support low-cost production and faster regulatory clearances.
Incorporating nanotechnology coatings into its grafts, Terumo seeks to enhance biocompatibility and minimize thrombosis risk. The firm is further focusing on surgeon training programs and collaboration with medical institutions to drive the use of its minimally invasive CABG solutions in high-growth geographies.
Guidant Group (9.1%)
Guidant Group is utilizing its robotic-assisted CABG expertise by adding AI-powered navigation systems to further improve procedural precision. The firm is bolstering its clinical trial pipeline to establish the long-term effectiveness of hybrid revascularization as a superior alternative to standard CABG.
Guidant is also increasing hospital collaborations in North America and Europe to drive combined treatment models combining CABG and PCI. Through regulatory clearances for new anastomotic devices, Guidant is strengthening product differentiation and market penetration.
Getinge AB (9.3%)
Getinge is fueling growth through strategic acquisitions in the cardiovascular segment, broadening its expertise in CABG-related technologies. The company is also creating automated perfusion systems to improve patient safety in on-pump procedures. Getinge is investing in sutureless grafting solutions, minimizing surgical complexity and enhancing procedural efficiency.
With a focus on sustainability and affordable healthcare solutions, the firm is customizing its CABG solutions for cost-conscious hospitals. Getinge is also enhancing its after-sales service and training solutions to facilitate long-term use of its surgical systems.
Other Key Players (48.1% Combined)
A number of other companies are major contributors to the coronary artery bypass graft market through advanced cardiovascular technologies and increased distribution networks. They include:
With the demand for coronary artery bypass graft procedures growing unabated, firms are focusing on technological innovations, regulatory clearances, and strategic partnerships to reinforce their market positions and enhance surgical outcomes.
The market is segmented based on technology, procedure, end user, and region.
the market is segmented into Off-Pump CABG, On-Pump CABG, and Others.
the market is segmented into Single-CABG surgery, Double-CABG surgery, Triple-CABG surgery, Quadruple-CABG surgery, and others.
the market is segmented into Hospitals, Academic & Research Institutes, and Independent Cardiology Centers.
Regionally, the coronary artery bypass graft market is analysed across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and the Middle East & Africa.
The overall market size for coronary artery bypass grafts market was USD 18,700.6 million in 2025.
The coronary artery bypass grafts market is expected to reach USD 24,887.3 million in 2035.
Rising prevalence of infectious diseases, cancer, and autoimmune disorders has significantly increased the demand for Western blot assays in clinical diagnostics.
The top key players that drives the development of coronary artery bypass graft market are Medtronic, Terumo Corporation, Guidant Group, Getinge AB, and Vitalitec International, Inc.
On-pump CABG by technology is coronary artery bypass graft market is expected to command significant share over the assessment period.
Explore Similar Insights
Coronary Artery Bypass Grafts Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
